Lung Injury, Acute Clinical Trial
Official title:
A Single-centre, Escalating Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Slow Intravenous Infusion of GW328267X in Healthy Volunteers
This study is a single dose evaluation using an open label dose escalating design. Cohort1
will consist of 3 healthy male volunteers. Each volunteer will receive a slow IV infusion
over 6 hours consisting of saline for 30 minutes (run in period), 8 mcg/h GW328267X for 1.5
hours (total dose of 12mcg) and 10 mcg/h GW328267X for 4 hours (total dose of 40 mcg).
Subjects will have continuous cardiac monitoring throughout the dosing period and up to 2
hours after cessation of the intravenous infusion. PK measurements and measurement of
erythropoietin and platelet activation will also be done. Samples for PK will be taken at 30
minute intervals during the infusion of GW328267X up to and including 1 hour after cessation
of the intravenous infusion. Samples for erythropoietin and platelet aggregation will be
done.
Cohort 2 is optional and may be carried out in the event that the dose of GW328267X given in
Cohort 1 is both well tolerated and subjects do not meet the stopping criteria. The decision
to proceed to Cohort 2 and the dose level will be made by the GSK Study Team and the
Investigator based on safety, tolerability and preliminary PK/PD data obtained in Cohort 1.
It is planned that the maximum total dose given to any subject will not exceed 150mcg.
Cohort 2 will consist of 3 healthy male volunteers and the study procedures for this
additional Cohort will be the same as that described for Cohort 1.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00498251 -
Prevention of Lung Edema After Thoracic Surgery
|
N/A | |
Completed |
NCT01597635 -
The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury
|
Phase 2 | |
Completed |
NCT00141726 -
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
|
Phase 2 | |
Completed |
NCT00996840 -
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
|
Phase 2 | |
Completed |
NCT03651817 -
Lung Protection Strategy in Open Heart Surgery: Which Tidal Volume is Better 8ml/kg or 6ml/kg
|
N/A | |
Recruiting |
NCT05680831 -
Pulmonary and Inflammatory Responses Following Exposure to a Low Concentration of Ozone or Clean Air
|
Phase 1 | |
Completed |
NCT03764319 -
Low Frequency, Ultra-low Tidal Volume Ventilation in Patients With ARDS and ECMO
|
N/A | |
Completed |
NCT01114009 -
Effects of Recruitment Maneuvers in Early Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) Patients
|
N/A | |
Terminated |
NCT00715338 -
Effects of Oxygen on Lung Tissue During Anesthesia
|
N/A | |
Recruiting |
NCT03202641 -
Open Lung Strategy, Gas Distribution and Right Heart Function in ARDS Patients
|
N/A | |
Completed |
NCT03828630 -
Lung Ultrasound to Detect Pulmonary Complications in Critically Ill Parturients
|
||
Completed |
NCT03905837 -
Impact of Lidocaine Administration on Postoperative Complications During Lung Resection Surgery
|
Phase 4 | |
Completed |
NCT03023670 -
Lung Protection and Pediatric Cardiac Surgery
|
N/A | |
Recruiting |
NCT05647967 -
Features of Regional Perfusion of Lung Consolidation
|
||
Recruiting |
NCT04289324 -
Open Lung Maneuvers During High Frequency Oscillatory Ventilation in Preterm Infants
|
N/A | |
Completed |
NCT05610475 -
Serum Level of Calpains Product as a Novel Biomarker of Acute Lung Injury Following Cardiopulmonary Bypass
|
N/A | |
Completed |
NCT05647382 -
Soluble VE-cadherin in Prediction and Diagnosis of Early Postoperative Hypoxemia After Cardiopulmonary Bypass
|
N/A | |
Recruiting |
NCT04511923 -
Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03637530 -
a Study Conducted About a New Mode of Ventilation in Laparoscopic Surgeries
|
N/A | |
Completed |
NCT04344184 -
SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)
|
Phase 2 |